Note 8 - Acquired Intangible Assets, Net

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Text Block]

Acquired Intangible Assets, Net

November

2007,

in connection with the termination of the agreement with Galderma which originally granted to Galderma the worldwide rights to commercialize, distribute, and market the ELEVESS product, the Company reacquired the worldwide rights and control of the future development and marketing of ELEVESS. The intangible asset realized during this process was the ELEVESS trade name which is fully amortized as of

December

31,

2016.

December

30,

2009,

in connection with the acquisition of Anika S.r.l., the Company purchased various intangible assets. The Company finalized the purchase price allocation relative to this acquisition during the

fourth

quarter of

2010.

January

2015,

the Company received CE Mark approval for HYALOSPINE which is an innovative adhesion prevention gel for use after spinal surgery, and was a component of the IPR&D intangible assets initially identified. As a result of this approval the Company has reclassified

$0.4

million from IPR&D to developed technology and began amortization on the HYALOSPINE asset.

2015,

the Company recorded an impairment charge totaling

$0.7

million to write-off in-process research and development that was recorded in connection with its acquisition of Anika S.r.l. Subsequent to an evaluation in the

fourth

quarter of the ongoing research and development efforts surrounding the Hemostatic Patch IPR&D project, the Company determined it would discontinue further development efforts needed to commercialize this technology. As a result of this decision, an impairment charge was recorded. These amounts are included in research and development expenses on our consolidated statements of operations.

The Company performed an annual assessment of IPR&D intangible assets as of

November

30,

2016.

Based upon that assessment, for the fiscal year

2016

there were no events or changes in circumstances that would result in a change in the carrying value of IPR&D.

Total amortization expense was

$1.1

million,

$1.1

million, and

$2.1

million for the years ended

December

31,

2016,

2015,

and

2014,

respectively. Amortization expense on intangible assets is expected to be approximately

$0.9

million in

2017,

$0.9

million annually through

2021,

and approximately

$2.8

million in aggregate thereafter.

Intangible assets consist of the following:

			December 31, 2016								December 31, 2015
	Gross Value		Accumulated Currency Translation Adjustment			Accumulated Amortization			Net Book Value		Net Book Value		Useful Life
Developed technology	$	17,100	$	(3,442	)	$	(6,816	)	$	6,842	$	7,959		15
In-process research & development		4,406		(1,433	)		-			2,973		3,099		Indefinite
Distributor relationships		4,700		(415	)		(4,285	)		-		-		5
Patents		1,000		(207	)		(381	)		412		473		16
Elevess trade name		1,000		-			(1,000	)		-		125		9
Total	$	28,206	$	(5,497	)	$	(12,482	)	$	10,227	$	11,656

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details